Merck Animal Health this week launched Nasalgen 3, a three-way intranasal vaccine that protects beef and dairy cattle from the most common pneumonia-causing viral pathogens.
Giving newborn calves intranasal vaccines is considered one of the most effective strategies to provide immunity quickly. According to Philip Griebel, a researcher at the Vaccine and Infectious Disease Organization at the University of Saskatchewan, research suggests the best approach to providing protection to the calf begins with a nasal vaccine in the first few weeks.
According to a Merck release, Nasalgen 3 has a six-and-a-half-month duration of immunity (DOI) against infectious bovine rhinotracheitis (IBR), an 11-week DOI against bovine respiratory syncytial virus (BRSV) and a three-month DOI against parainfluenza 3 (PI3).
“Nasalgen 3 mimics natural exposure to the most common pneumonia viruses,” says Scott Nordstrom, DVM, associate director of ruminant life cycle management at Merck Animal Health in the release. “The intranasal administration of Nasalgen 3 stimulates a strong, early immune response because the vaccine antigens are delivered to mucosal surfaces in the nose – an area loaded with immunologically active tissues.”
Nasalgen intranasal vaccines avoid interference from maternal antibodies in colostrum that can block injectable vaccines and are less stressful on calves compared to similar injectable vaccinations, Merck says. Additionally, Nasalgen 3 also is designed with an IBR that is not temperature-sensitive, so the vaccine will replicate and protect in a moderate to high temperature environment.
“If producers are working cattle in warm temperatures, Nasalgen 3 will still replicate,” . Nordstrom says in the release. “The IBR antigen elicits a rapid interferon response as well, which provides non-specific protection against many viruses. Cattle are protected early on and then develop both a serum and mucosal antibody response within two weeks of vaccination.”
To learn more, visit Nasalgen.com